A quantitative autoradiographic study of muscarinic cholinergic receptor subtypes in the brains of pyrithiamine-treated rats.
Previous studies describe decreased acetylcholine synthesis in brain as well as neurobehavioral evidence for a central muscarinic cholinergic deficit in pyrithiamine-induced thiamine-deficient rats. In order to further evaluate this possibility, quantitative autoradiographic procedures using [3H]quinuclidinyl benzilate (for total muscarinic binding sites), [3H]pirenzepine (for muscarinic M1 sites) and [3H]AF-DX 384 (for muscarinic M2 sites) were performed at early (presymptomatic) and late (symptomatic) stages of thiamine deficiency induced in rats by administration of the central thiamine antagonist, pyrithiamine. No significant alterations in densities of M1, M2 or total muscarinic binding sites were observed in any brain structure evaluated at either early or late stages of thiamine deficiency. These findings do not support a major role for modifications of muscarinic cholinergic function in the pathogenesis of the neurological symptoms of thiamine deficiency.
Rao
V L
VL
Neuroscience Research Unit, Hôpital Saint-Luc, University of Montreal, QC, Canada.
Mousseau
D D
DD
Butterworth
R F
RF
D000818:Animals; D000963:Antimetabolites; D001345:Autoradiography; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D010890:Pirenzepine / Q000031:analogs & derivatives / Q000378:metabolism; D011745:Pyrithiamine; D011813:Quinuclidinyl Benzilate / Q000378:metabolism; D011869:Radioligand Assay; D051381:Rats; D017207:Rats, Sprague-Dawley; D011976:Receptors, Muscarinic / Q000032:analysis*; D013832:Thiamine Deficiency / Q000139:chemically induced*
D000963:Antimetabolites; D011976:Receptors, Muscarinic; C065959:AFDX 384; D010890:Pirenzepine; D011745:Pyrithiamine; D011813:Quinuclidinyl Benzilate